Conference Summaries: Day Three<BR> Friday, September 15, 2000

The Body Covers: The 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy Coverage

Conference Summaries: Day Three
Friday, September 15, 2000

Genes, Diet, and Atherogenic Dyslipidemia
Ronald Krauss
HIV Protease Inhibitors Increase Secretion of Apolipoprotein B-lipoproteins from Hepatoma Cells by Preventing Proteasomal Degradation
Henry Ginsberg
Differences in Postprandial Lipid Metabolism in Patients with PI-Associated and NRTI-Associated Lipodystrophy
Lisa Ware
Increased tPA Antigen Levels in the HIV Lipodystrophy Syndrome are Reduced in Response to Metformin
Colleen Hadigan
Role of Endothelial Dysfunction in Atherosclerosis
Frank Ruschitzka
Metabolic Complications: The Need for Perspective
Matthius Egger
Use of HIV Protease Inhibitors is Associated with Endothelial Dysfunction
James Stein
IMT as Cardiovascular Risk Marker in HIV+ Patients Treated and Untreated with Protease Inhibitors
Renato Maserati
Lessons Learned from Switching Antivirals
William Powderly
Lipodystrophy and Metabolic Abnormalities in a Cross-Sectional Study of Participants in Randomized-Controlled Studies of Combination Antiretroviral Therapy (ARV)
Matthew Law
Serum and Urine Markers of Bone Mineral Metabolism in HIV-Infected Patients Taking Protease Inhibitor-Containing Potent Antiretroviral Therapy
Pablo Tebas
Longitudinal Analysis of Bone Mineral Density (BMD) in HIV-infected Patients Treated with HAART: Changes in BMD Correlate with Change in Subcutaneous Fat; with an Additional Independent Effect of Indinavir Therapy to Increase BMD
David Nolan
Osteopenia in HIV-Infected Men: Association with Lactic Acidemia and Lower Weight Pre-Antiretroviral Therapy
Andrew Carr
Case-control Study of Avascular Necrosis (AVN) in HIV-Infected Patients
Marshall Glesby
Metabolic and Clinical Evaluation of Lipodystrophy 48 Weeks After Switching from Two Nucleoside Reverse Transcriptase Inhibitors/Protease Inhibitor to Two Nucleoside Reverse Transcriptase Inhibitors/Abacavir (French Substudy, CNA 30017)
W. Rozenbaum, et al.
Switching from Protease Inhibitor to Nevirapine-Based Potent Antiretroviral Therapy Increases Lean Body Mass
K.E. Yarasheski, et al.
HIV-Protease Inhibitor Switch to Nevirapine Improves Insulin Tolerance but Does not Correct Adipose Tissue Maldistribution
K.E. Yarasheski, et al
A Randomized, Multicentre Study of Protease Inhibitor Substitution in Aviraemic Patients with Lipodystrophy (LD): 48-Week Data
A. Carr et al.
Fat Redistribution Syndrome/Lipodystrophy and Anabolic Agents: Results of a Large Multicenter U.S. Study
G. McComsey, et al.

Previous Day's Sessions

Return to The Body's coverage of
The 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV.

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.